<DOC>
	<DOCNO>NCT01964963</DOCNO>
	<brief_summary>The purpose study examine safety efficacy long-term treatment alogliptin ( Nesina ) patient mild type 2 diabetes mellitus routine clinical setting .</brief_summary>
	<brief_title>Alogliptin Tablets Special Drug Use Surveillance : Mild Type 2 Diabetes Mellitus</brief_title>
	<detailed_description>This special drug use surveillance long-term use alogliptin , design investigate safety efficacy treatment alogliptin patient mild type 2 diabetes mellitus routine clinical setting . Participants patient mild type 2 diabetes mellitus . The planned sample size 20,000 . The usual adult dosage oral use 1 alogliptin tablet ( 25 mg alogliptin ) daily .</detailed_description>
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<mesh_term>Alogliptin</mesh_term>
	<criteria>Patients HbA1c ( JDS value ) â‰¤7.0 % time enrolment ( within 3 month initiation Nesina therapy ) , regardless use antidiabetic medication . Patients contraindicate Nesina 1 . Patients severe ketosis , diabetic coma precoma , type 1 diabetes mellitus . 2 . Patients severe infection , pre postoperative patient , patient serious traumatic injury . 3 . Patients history hypersensitivity ingredient Nesina .</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2016</verification_date>
</DOC>